Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
BACKGROUND: Cytomegalovirus infection in renal transplant recipients is a major clinical problem, with both short and long term sequelae. Infection can occur as a result of reactivation of latent virus or new infection from donor tissues. The impact of donor and recipient serostatus on viremia is w...
| Prif Awduron: | , , , , , , , , |
|---|---|
| Fformat: | Journal article |
| Iaith: | English |
| Cyhoeddwyd: |
2008
|
| _version_ | 1826281574443778048 |
|---|---|
| author | Hughes, D Hafferty, J Fulton, L Friend, P Devaney, A Loke, J Welsh, K Handa, A Klenerman, P |
| author_facet | Hughes, D Hafferty, J Fulton, L Friend, P Devaney, A Loke, J Welsh, K Handa, A Klenerman, P |
| author_sort | Hughes, D |
| collection | OXFORD |
| description | BACKGROUND: Cytomegalovirus infection in renal transplant recipients is a major clinical problem, with both short and long term sequelae. Infection can occur as a result of reactivation of latent virus or new infection from donor tissues. The impact of donor and recipient serostatus on viremia is well recognised, with seronegative recipients at greatest risk after transplantation of an organ from a seropositive donor. However, the impact of grafting such organs into seropositive recipients is less clear. OBJECTIVES: To assess the impact of recipient serostatus on the risk of CMV antigenemia in a large renal transplant cohort. STUDY DESIGN: We prospectively quantified CMV antigenemia over time in a cohort of 486 recipients. We analysed the antigenemia status according to donor and recipient serostatus. RESULTS: Antigenemia was most common in seronegative recipients of organs from seropositive donors (D+/R-). Nevertheless, we observed that even in CMV seropositive recipients, the impact of donor serostatus on CMV antigenemia is still substantial (p=0.006; OR=2.2). CONCLUSIONS: In this large study, donor serostatus clearly plays a significant role in determining CMV risk, even in seropositive recipients. |
| first_indexed | 2024-03-07T00:30:51Z |
| format | Journal article |
| id | oxford-uuid:7fbf1bc5-d0d2-48af-a3a7-f3dff31347df |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:30:51Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:7fbf1bc5-d0d2-48af-a3a7-f3dff31347df2022-03-26T21:18:57ZDonor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7fbf1bc5-d0d2-48af-a3a7-f3dff31347dfEnglishSymplectic Elements at Oxford2008Hughes, DHafferty, JFulton, LFriend, PDevaney, ALoke, JWelsh, KHanda, AKlenerman, P BACKGROUND: Cytomegalovirus infection in renal transplant recipients is a major clinical problem, with both short and long term sequelae. Infection can occur as a result of reactivation of latent virus or new infection from donor tissues. The impact of donor and recipient serostatus on viremia is well recognised, with seronegative recipients at greatest risk after transplantation of an organ from a seropositive donor. However, the impact of grafting such organs into seropositive recipients is less clear. OBJECTIVES: To assess the impact of recipient serostatus on the risk of CMV antigenemia in a large renal transplant cohort. STUDY DESIGN: We prospectively quantified CMV antigenemia over time in a cohort of 486 recipients. We analysed the antigenemia status according to donor and recipient serostatus. RESULTS: Antigenemia was most common in seronegative recipients of organs from seropositive donors (D+/R-). Nevertheless, we observed that even in CMV seropositive recipients, the impact of donor serostatus on CMV antigenemia is still substantial (p=0.006; OR=2.2). CONCLUSIONS: In this large study, donor serostatus clearly plays a significant role in determining CMV risk, even in seropositive recipients. |
| spellingShingle | Hughes, D Hafferty, J Fulton, L Friend, P Devaney, A Loke, J Welsh, K Handa, A Klenerman, P Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. |
| title | Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. |
| title_full | Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. |
| title_fullStr | Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. |
| title_full_unstemmed | Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. |
| title_short | Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. |
| title_sort | donor and recipient cmv serostatus and antigenemia after renal transplantation an analysis of 486 patients |
| work_keys_str_mv | AT hughesd donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients AT haffertyj donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients AT fultonl donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients AT friendp donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients AT devaneya donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients AT lokej donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients AT welshk donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients AT handaa donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients AT klenermanp donorandrecipientcmvserostatusandantigenemiaafterrenaltransplantationananalysisof486patients |